Clostridium difficile (CDI)

Educational ExhibitTM: Helping Bring The First New Therapy to Segment in 30 Years

Optimer Pharmaceuticals was developing a new drug for the treatment of Clostridium difficile infections (CDI). Their new drug would be the first new entry into this marketing segment in nearly 30 years.  The Educational ExhibitTM assisted Optimer in this breaking into this well-established segment.

Through the development of a custom branded, data rich, disease-state program, the Educational ExhibitTM addressed all of the above points and more.

The program reached over 1,800 targeted clinicians at four national conferences. Due to the settled established nature of the CDI segment, audiences were appreciative of the new data and updated details on CDI outbreaks and varying global mutations that clinicians typically face.